Maximus, Inc. (MMS) Shares Sold by Smithfield Trust Co.
Smithfield Trust Co. lowered its position in shares of Maximus, Inc. (NYSE:MMS) by 0.7% during the second quarter, Holdings Channel reports. The fund owned 2,800 shares of the health services provider’s stock after selling 20 shares during the period. Smithfield Trust Co.’s holdings in Maximus were worth $175,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Neuburgh Advisers LLC boosted its position in shares of Maximus by 1.9% in the first quarter. Neuburgh Advisers LLC now owns 1,696 shares of the health services provider’s stock worth $105,000 after buying an additional 32 shares during the last quarter. Acrospire Investment Management LLC boosted its position in shares of Maximus by 183.3% in the first quarter. Acrospire Investment Management LLC now owns 1,700 shares of the health services provider’s stock worth $106,000 after buying an additional 1,100 shares during the last quarter. Glen Harbor Capital Management LLC boosted its position in shares of Maximus by 1.9% in the first quarter. Glen Harbor Capital Management LLC now owns 2,332 shares of the health services provider’s stock worth $145,000 after buying an additional 44 shares during the last quarter. Elkfork Partners LLC boosted its position in shares of Maximus by 1.9% in the first quarter. Elkfork Partners LLC now owns 2,968 shares of the health services provider’s stock worth $185,000 after buying an additional 56 shares during the last quarter. Finally, Violich Capital Management Inc. purchased a new position in shares of Maximus during the first quarter worth approximately $217,000. 97.89% of the stock is owned by institutional investors and hedge funds.
Shares of Maximus, Inc. (NYSE MMS) opened at 60.90 on Wednesday. Maximus, Inc. has a 12-month low of $43.69 and a 12-month high of $64.97. The company has a 50 day moving average price of $61.60 and a 200 day moving average price of $60.73. The firm has a market cap of $3.95 billion, a PE ratio of 19.97 and a beta of 1.39.
Maximus (NYSE:MMS) last issued its quarterly earnings results on Thursday, August 3rd. The health services provider reported $0.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.03. The company had revenue of $600.40 million during the quarter, compared to the consensus estimate of $614.12 million. Maximus had a return on equity of 25.08% and a net margin of 8.43%. Maximus’s revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.79 EPS. On average, analysts forecast that Maximus, Inc. will post $3.12 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 31st. Shareholders of record on Tuesday, August 15th will be issued a $0.045 dividend. The ex-dividend date is Friday, August 11th. This represents a $0.18 annualized dividend and a yield of 0.30%. Maximus’s dividend payout ratio (DPR) is presently 5.73%.
COPYRIGHT VIOLATION NOTICE: “Maximus, Inc. (MMS) Shares Sold by Smithfield Trust Co.” was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/08/09/maximus-inc-mms-shares-sold-by-smithfield-trust-co.html.
A number of equities analysts have commented on the company. BidaskClub cut Maximus from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. Maxim Group set a $66.00 target price on Maximus and gave the company a “hold” rating in a report on Thursday, August 3rd. ValuEngine cut Maximus from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th. KeyCorp reissued a “sector weight” rating on shares of Maximus in a report on Thursday, May 25th. Finally, Zacks Investment Research raised Maximus from a “sell” rating to a “hold” rating in a report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. Maximus presently has a consensus rating of “Hold” and a consensus price target of $62.17.
In other news, President Bruce Caswell sold 17,197 shares of the business’s stock in a transaction on Thursday, May 11th. The shares were sold at an average price of $62.47, for a total transaction of $1,074,296.59. Following the completion of the sale, the president now directly owns 27,904 shares of the company’s stock, valued at approximately $1,743,162.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Richard A. Montoni sold 30,000 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $62.81, for a total transaction of $1,884,300.00. Following the sale, the chief executive officer now directly owns 584,114 shares of the company’s stock, valued at $36,688,200.34. The disclosure for this sale can be found here. Insiders sold a total of 109,636 shares of company stock valued at $6,874,122 over the last quarter. 3.10% of the stock is currently owned by insiders.
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Want to see what other hedge funds are holding MMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maximus, Inc. (NYSE:MMS).
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.